Last reviewed · How we verify
Geodon (Ziprasidone)
Ziprasidone is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain.
Ziprasidone is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain. Used for Schizophrenia, Acute agitation in patients with schizophrenia, Bipolar I disorder (acute manic or mixed episodes).
At a glance
| Generic name | Geodon (Ziprasidone) |
|---|---|
| Sponsor | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. |
| Drug class | Atypical antipsychotic |
| Target | Dopamine D2 receptor, Serotonin 5-HT2A receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | Phase 3 |
Mechanism of action
Ziprasidone antagonizes dopamine D2 receptors, which reduces psychotic symptoms, and also blocks serotonin 5-HT2A receptors, which may improve mood and reduce extrapyramidal side effects. It has a rapid onset of action and is notable for minimal weight gain compared to other atypical antipsychotics.
Approved indications
- Schizophrenia
- Acute agitation in patients with schizophrenia
- Bipolar I disorder (acute manic or mixed episodes)
Common side effects
- Somnolence
- Akathisia
- Extrapyramidal symptoms
- Dizziness
- Nausea
- QT prolongation
- Rash
Key clinical trials
- An Exploratory Analysis of Immune and Inflammatory Response Associated With Clozapine (PHASE4)
- Estimating and Reducing the Cardiovascular Risk of Patients With Schizophrenia Drugs From Lipid Measures and Ischemic Electrocardiographic Changes (PHASE3)
- Maternal And Infant Antipsychotic Study
- A Study to Assess Stroke Risk Among Users of Typical Versus Atypical Antipsychotics Stratified by Broad Age Group
- Proposal To Develop A Rapid And Cost-Effective Diagnostic Test For Schizophrenia (PHASE1)
- Ziprasidone in Bipolar Disorder With Comorbid Lifetime Panic or Generalized Anxiety Disorder(GAD) (PHASE4)
- Impact of Aripiprazole Once Monthly Medications on Changes in Brain Structure and Metabolism (PHASE4)
- Efficacy and Safety of Iloperidone Compared With Placebo and Active Control in Subjects With Acute Schizophrenia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Geodon (Ziprasidone) CI brief — competitive landscape report
- Geodon (Ziprasidone) updates RSS · CI watch RSS
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. portfolio CI